There are two types of laboratory validation studies:
- Analytical (Performance) Validation evaluates whether a laboratory test accurately and reliably measures the analyte it is intended to measure. This includes establishing performance characteristics such as accuracy, precision, analytical sensitivity, analytical specificity, reportable range, reference intervals, and reproducibility to demonstrate that the assay performs consistently under validated laboratory conditions.
- Clinical Validation evaluates whether the laboratory result is meaningfully associated with the intended clinical or biological condition, outcome, or population. It establishes the clinical relevance and utility of the test by demonstrating that the measured biomarker or analyte is supported by scientific evidence to reflect the biological process or clinical context for which the test is intended.
A Food Zoomer peptide-level antibody panel containing hundreds of dairy, wheat, corn, soy, egg, peanut, lectin, and aquaporin antigens presents unique challenges for clinical validation because there is no single universally accepted clinical reference standard or disease endpoint against which all measured antibodies can be compared. Different food-specific antibodies may reflect diverse biological phenomena, including normal immune exposure, oral tolerance, transient immune responses, increased intestinal permeability, or immune reactivity, and their clinical significance varies among individuals and clinical contexts.
Additionally, performing traditional clinical validation would require large, well-characterized prospective studies for each individual peptide or antigen, with standardized clinical outcomes and appropriate comparator methods. Given the large number of analytes, the heterogeneity of foods and peptides, interindividual variability in immune responses, dietary exposures, and the absence of consensus diagnostic criteria for most food antibody targets, such studies would be extraordinarily complex, time-consuming, and costly.
As a result, validation efforts for multiplex peptide arrays are generally focused on demonstrating robust analytical performance, while clinical interpretation relies on the broader body of published scientific literature supporting the biological relevance of the measured antibodies and should always be interpreted within the context of the patient's clinical history and other relevant findings.
Vibrant does have a published clinical trial on food sensitivity testing and food elimination diets- the Personalized Food Elimination Diet: A Clinical Trial Based on Food Sensitivity Assessment revealed that serological assessment followed by a personalized elimination diet reduced symptoms, improved antibody titers, and favorably influenced provider assessments of patient response.